Clarifying the immunosuppressive role of the TGF-β signaling pathway within tumors (3–5) and converting the tumor-suppressive microenvironment by remodeling TGF-β-initiated transmembrane signaling have spurred therapeutic progress in TGF-β-related drugs, including molecular blockers, CAR-T cells, and bispecific antibodies. This evidence concerns the gene TGFB1 and neoplasm.